Macquarie Group LTD T Scan Therapeutics, Inc. Transaction History

Macquarie Group LTD

$90.3 Billion
Q3 2024

A detailed history of Macquarie Group LTD transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 1,047 shares of TCRX stock, worth $3,224. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,047

Holding current value

$3,224

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2024 Nov 14, 2024	BUY	$4.97 - $7.49 $5,203 - $7,842	1,047 New	1,047 $5,000
Q1 2024 May 14, 2024	BUY	$4.89 - $8.3 $7,912 - $13,429	1,618 New	1,618 $12,000

Others Institutions Holding TCRX

# of Institutions

Shares Held

41.8M

Call Options Held

Put Options Held

Lynx1 Capital Management LP San Juan, PR

5.22M
Shares

$16.1 Million
9.31% of portfolio
Eco R1 Capital, LLC San Francisco, CA

5M
Shares

$15.4 Million
1.08% of portfolio
Black Rock Inc. New York, NY

4.46M
Shares

$13.7 Million
0.0% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

4.4M
Shares

$13.6 Million
0.04% of portfolio
Bvf Inc San Francisco, CA

2.99M
Shares

$9.21 Million
0.47% of portfolio

View Full List

About TScan Therapeutics, Inc.

Ticker TCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,929,800
Market Cap $58.3M
Description
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...

More about TCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account